https://www.selleckchem.com/pr....oducts/tegatrabetan.
in blood banks; a pilot study showed that using this novel NAT assay could reduce the risk of TTM. The prototype HIV/HCV/HBV/malaria NAT assay was effective in detecting infected candidate donors and has good prospects to be applied in routine screening for preventing TTM. The prototype HIV/HCV/HBV/malaria NAT assay was effective in detecting infected candidate donors and has good prospects to be applied in routine screening for preventing TTM. People who inject drugs (PWID) are a medically and socially vulnerable population with a
Like
Comment
Share
